

CARDIODAN® 1.25

Palatable tablets

Inotropic and Vasodilator for Congestive Heart Failure



Formulation

Each 200 mg flavored tablet contains: Pimobendan 1.25 mg; Excipients q.s.ad. 1 tablet

Indications

-Treatment of canine congestive heart failure (CHF) caused by dilated cardiomyopathy or valve regurgitation (mitral and/or tricuspid valve regurgitation). -Treatment of dilated cardiomyopathy (CMD) in large breed dogs. When used in cases of CMD in large breed dogs, the time to onset of CHF or sudden death is significantly prolonged and results in prolongation of the life span of the animal. -Treatment of CMD in the preclinical stage (asymptomatic with increased end-systolic and end-diastolic diameters of the left ventricle), mainly in Doberman Pinschers after echocardiographic diagnosis of heart disease. -Treatment of dogs with myxomatous mitral valve disease (MVD) in the preclinical phase (asymptomatic with systolic mitral murmur and evidence of an enlarged heart) to delay the onset of clinical symptoms of heart failure.

Dosage and Administration

Orally. The dose is 0.25 mg/kg of body weight every twelve hours (morning and night) for a total daily administration of 0.5 mg/kg (in practice 1/2 tablet of Cardiodan® 1.25 for every 2-5 kg every 12 hours). Should be administered one hour before meals.

Commercial Presentation

Box x 10 tablets, Box x 30 tablets, Box x 60 tablets,

SENASA Registry

Reg. SENASA Peru: F.012.031.I.00022



Este contenido es una referencia informativa y no debe ser considerado como recomendaciones de uso.